{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["10(2)"],"submitter":["Montagne A"],"pubmed_abstract":["<h4>Abstract</h4>Early detection of ultrahigh-risk diffuse large B-cell lymphoma (DLBCL) is an unmet medical need to aid patient stratification for alternative treatment approaches. Metabolomics applied to biofluids of patients with cancer has emerged as a novel omics that could provide important information to better stratify these patients. In this work, the authors performed a retrospective study by nuclear magnetic resonance (NMR)-based metabolomics using plasma samples at diagnosis from 154 randomized patients with DLBCL treated by R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (from the phase 3 REMARC [Reduced-intensity Maintenance therapy with Rituximab After R-CHOP in elderly patients with DLBCL] trial). Remarkably, a combination of 3 circulating met"],"journal":["Blood advances"],"pagination":["358-366"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12828828"],"repository":["biostudies-literature"],"pubmed_title":["Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis."],"pmcid":["PMC12828828"],"pubmed_authors":["Morschhauser F","Chartier L","Ricci R","Baud V","Haioun C","Bertho G","Brisou G","Ghesquieres H","Gaulard P","Thieblemont C","Feugier P","Oberic L","Giraud N","Montagne A","Jardin F","Bennani Y","Papastergiou T","Rossi C","Ribrag V"],"additional_accession":[]},"is_claimable":false,"name":"Risk stratification of patients with diffuse large B-cell lymphoma using plasma NMR-based metabolomics at diagnosis.","description":"<h4>Abstract</h4>Early detection of ultrahigh-risk diffuse large B-cell lymphoma (DLBCL) is an unmet medical need to aid patient stratification for alternative treatment approaches. Metabolomics applied to biofluids of patients with cancer has emerged as a novel omics that could provide important information to better stratify these patients. In this work, the authors performed a retrospective study by nuclear magnetic resonance (NMR)-based metabolomics using plasma samples at diagnosis from 154 randomized patients with DLBCL treated by R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) (from the phase 3 REMARC [Reduced-intensity Maintenance therapy with Rituximab After R-CHOP in elderly patients with DLBCL] trial). Remarkably, a combination of 3 circulating met","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-06-06T22:05:26.449Z","creation":"2026-06-05T03:12:22.451Z"},"accession":"S-EPMC12828828","cross_references":{"pubmed":["41056515"],"doi":["10.1182/bloodadvances.2025017248"]}}